InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,386.83
(
-0.79%
)
Post# of 251714
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 217462

Friday, 03/02/2018 10:11:51 AM

Friday, March 02, 2018 10:11:51 AM

Post# of 251714
Mavyret’s market share grows in week ending 2/23/18 (according to IMS):

• ABBV/ENTA’s HCV-new-patient share=39.2%, up slightly from the prior week and matching the highest-ever figure logged in the week ending 2/9/18 (#msg-138602647).

• ABBV/ENTA’s HCV-total-patient-share=35.0%, the highest-ever figure.

(Almost all of ABBV/ENTA’s US HCV business now comes from Mavyret.)

The gap between Mavyret’s NRx% and TRx% is narrowing insofar as most US Harvoni patients are now being treated for 8 weeks rather than 12 weeks; thus GILD’s advantage vs ABBV/ENTA in average duration per patient is shrinking.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up